Effect of intravenous immunoglobulin in immune thrombocytopenia.
about
RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME)Childhood immune thrombocytopenia: Clinical presentation and managementImmunoglobulin G-mediated inflammatory responses develop normally in complement-deficient miceDo the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV anti-D and to IV gammaglobulin predict response to subsequent splenectomy?A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura.Immune thrombocytopenic purpura - current management practices.Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopeniaIntravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells.Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia.Absence of cytokine modulation following therapeutic infusion of intravenous immunoglobulin or anti-red blood cell antibodies in a mouse model of immune thrombocytopenic purpura.The use of vinca alkaloids in preparation for splenectomy of corticosteroid refractory chronic immune thrombocytopenic purpura patients.Fc receptors in immune thrombocytopenias: a target for immunomodulation?Patients' benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies.ITP: a historical perspective.Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.ImmunoglobulinâG dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia.Management of children and adolescents with primary immune thrombocytopenia: controversies and solutions.Management of immune thrombocytopenic purpura: an update.Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura.The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.High dose intravenous gammaglobulins in autoimmune disorders: mode of action and therapeutic uses.Long-term response in a patient with ITP following low dose anti-D immunoglobulin therapy.High dose Intravenous Anti-D Immune Globulin is More Effective and Safe in Indian Paediatric Patients of Immune Thrombocytopenic Purpura.Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain.Mechanism of action of intravenous immunoglobulin in immune-mediated cytopenias.Beneficial effect of intravenous gammaglobulin in a patient with complement-mediated autoimmune thrombocytopenia due to IgM-anti-platelet antibodies.Treatment of adult patients with idiopathic thrombocytopenic purpura with intravenous immunoglobulin: effects on circulating T cell subsets and PWM-induced antibody synthesis in vitro.The use of intravenous immunoglobulin (endobulin) in patients with immune thrombocytopenia.Intravenous usage of gammaglobulin: humoral immunodeficiency, immune thrombocytopenic purpura, and newer indications.High-dose intravenous immunoglobulin for post-transfusion purpura.The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease.Therapy with intravenous immunoglobulin G (ivIgG) during pregnancy for fetal alloimmune (HPA-1a(Zwa)) thrombocytopenic purpura.The treatment of autoimmune thrombocytopaenic purpura with anti-D immunoglobulin: similar platelet responses in homozygous and heterozygous Rh(D) positive patients.Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases.Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial.Clinical evaluation of plasma exchange and high dose intravenous immunoglobulin in a patient with Isaacs' syndrome.IVIG in APS pregnancy.Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases.Precautions surrounding blood transfusion in autoimmune haemolytic anaemias are overestimated
P2860
Q26824798-A6F3B66F-3764-4EBE-A516-9321CB00661AQ27023294-BA0BD0B7-786B-4AB6-8023-FCE303AB3B1DQ28593561-2ADDEF34-E7F6-4C10-8F27-0D74057A2337Q33336653-057C8FC2-4022-4E02-A63E-93EFDD8D9264Q33336796-E1C2184C-1EC7-4198-A40A-69DC964094B4Q33363927-B80E19A3-A474-4BE4-9EB5-5BE325FF4270Q33364381-51DB4B05-955D-43B5-BD42-2785608926DCQ33370766-96EC94EC-85D4-444D-A509-2DBB73E1BBC6Q33371273-E3511E61-4124-40BC-AAF2-4F9DBE513D77Q33373425-BB6AF1A7-DDC9-45ED-B5FE-1BF31F3E2B2FQ33374445-FE4E5150-1EAE-4039-9911-DD1A63BD1961Q33376574-ECC5C2A8-57C2-4366-8D12-1277548AF64EQ33380494-3966C254-5672-4809-BC26-6FE5BAA478BAQ33388078-71C0B198-8B6E-42B7-8560-470E1730D745Q33394791-DE759B1D-451A-43E4-9D3E-C02D6E42900CQ33396204-159EA4BC-656D-48E1-911E-5FFFE14F5A69Q33401630-9728D5C5-56AC-4633-BC94-8FBB6D98F8D4Q33402387-EDC3F4BF-7FD3-4E03-B301-89A7AE40F3B8Q33403726-76630B0C-372B-479D-9711-E8C4558198D5Q33410674-4FE11EAB-2B33-49C9-A1DC-DECD3F3D02F5Q33414420-B7DE1446-FC69-4924-8694-CDA8DF7D20CAQ33415447-4895CDD3-A7E5-4A83-B079-0327307865D4Q33420004-3ABF8297-FD91-4D41-9351-CC5951F4A315Q33439415-EAFDAB96-C534-478C-9AE2-896E2EACBE59Q33443533-2535B452-724F-4F5B-8F7A-93DEFA27A548Q33446069-CE80B722-51BE-4D0C-9C67-2DECA6C7FC50Q33451500-6A590365-E744-43B3-9A04-46E58FCC71BBQ33452423-770029CA-ECDD-420C-935D-0F72100E08C3Q33455834-F8D5FF3F-1525-42EF-BE63-1B0E8392328EQ33460250-07604040-DFB1-4696-B0E1-7B959BDB01F0Q33460445-64BCEAD3-DB60-4DEF-988A-928BDCD7EC93Q33477547-00920C39-0F0D-490E-A7F9-340433686561Q33496889-600DE274-87A8-4259-A8E1-E65F72E4E806Q33500034-7F329583-24A0-49B5-A4B5-0F565873A213Q33596381-739D7312-BE48-4D92-AB39-7DE498F1417FQ33596386-5A46DB19-7A34-443A-82E9-DC0F9D3A4C87Q33732789-53A8DE6E-8AF5-4F3E-871B-55213B47F83DQ35918396-250A4470-1738-46DD-91F6-F52386B44AAEQ35963373-BCEF6BFA-222E-4024-A947-5DD8376437EDQ36220079-5D32F4FE-406A-42F2-8ACF-38F6AE60A64E
P2860
Effect of intravenous immunoglobulin in immune thrombocytopenia.
description
1983 nĂŽ lĹŤn-bĂťn
@nan
1983 ŐŠŐ¸ÖŐĄŐŻŐĄŐśŐŤ Ő
Ő¸ÖŐŹŐŤŐ˝ŐŤŐś Ő°ÖŐĄŐżŐĄÖŐĄŐŻŐ¸ÖŐĄŐŽ ŐŁŐŤŐżŐĄŐŻŐĄŐś ŐľÖ
Ő¤Ő¸ÖŐĄŐŽ
@hyw
1983 ŐŠŐžŐĄŐŻŐĄŐśŐŤ Ő°Ő¸ÖŐŹŐŤŐ˝ŐŤŐś Ő°ÖŐĄŐżŐĄÖŐĄŐŻŐžŐĄŐŽ ŐŁŐŤŐżŐĄŐŻŐĄŐś Ő°Ő¸Ő¤ŐžŐĄŐŽ
@hy
1983ĺš´ăŽčŤć
@ja
1983ĺš´čŤć
@yue
1983ĺš´čŤć
@zh-hant
1983ĺš´čŤć
@zh-hk
1983ĺš´čŤć
@zh-mo
1983ĺš´čŤć
@zh-tw
1983嚴莺ć
@wuu
name
Effect of intravenous immunoglobulin in immune thrombocytopenia.
@ast
Effect of intravenous immunoglobulin in immune thrombocytopenia.
@en
type
label
Effect of intravenous immunoglobulin in immune thrombocytopenia.
@ast
Effect of intravenous immunoglobulin in immune thrombocytopenia.
@en
prefLabel
Effect of intravenous immunoglobulin in immune thrombocytopenia.
@ast
Effect of intravenous immunoglobulin in immune thrombocytopenia.
@en
P1433
P1476
Effect of intravenous immunoglobulin in immune thrombocytopenia.
@en
P2093
P304
P356
10.1016/S0140-6736(83)90175-7
P407
P577
1983-07-01T00:00:00Z